STOCK TITAN
  1. Home
  2. News
  3. ALC

Alcon Inc. Ordinary Shares - ALC STOCK NEWS

Welcome to our dedicated page for Alcon Ordinary Shares news (Ticker: ALC), a resource for investors and traders seeking the latest updates and insights on Alcon Ordinary Shares stock.

Alcon Inc. Ordinary Shares (symbol: ALC) is a premier American-Swiss healthcare company headquartered in Geneva, Switzerland, and incorporated in Fribourg, Switzerland. Renowned globally for its eye care products, Alcon excels in vision care and surgical segments, making it a leader in the eye care industry. Having spun off from Novartis in April 2019, Alcon now independently operates to enhance the quality of life through innovative vision products.

Alcon’s vision care segment includes a wide range of products such as contact lenses, lens care solutions, and ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon boasts significant control over the U.S. contact lens market. Their surgical segment offers advanced solutions like intraocular lenses (IOLs), ophthalmic surgical equipment, and consumables used during surgeries. Notable products include the Centurion phacoemulsification device and the Clareon, PanOptix, and Vivity IOLs.

Recently, Alcon launched the Clareon Vivity, which is the world’s first non-diffractive extended depth of focus (EDOF) intraocular lens. This innovative IOL incorporates wavefront-shaping technology, offering superior visual outcomes for cataract patients seeking presbyopia correction. The Clareon platform enhances Alcon's portfolio, which already includes the highly successful PanOptix lenses.

Financially, Alcon has shown robust growth. For Q4 2023, Alcon's sales reached $2.3 billion, marking an 8% increase from the previous year. Diluted EPS was $0.86, reflecting a 78% increase, and core diluted EPS was $0.70, up 67%. Alcon also reported a strong cash flow, with $937 million generated from operating activities in the first nine months of 2023.

Alcon's dedication to innovation and quality in eye care is further evidenced by its extensive research and development initiatives. The company engages in partnerships with eye care professionals and offers educational resources through the Alcon Experience Academy. Through consistent advancements and a customer-centric approach, Alcon continues to lead in enhancing sight and improving lives globally.

News

Alcon Strengthens Leadership in IOL Innovation with the launch of the Clareon Presbyopia Correcting IOLs in India

Rhea-AI Summary
Alcon launches Clareon Family of intraocular lenses in India, offering exceptional clarity and predictable refractive outcomes. The new IOL material has low levels of haze and nanoglistenings, setting it apart from competitors. The Clareon platform includes PanOptix and Vivity technologies, with high patient satisfaction rates. Alcon aims to revolutionize cataract surgery with innovative IOL technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
none
-
News

Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone

Rhea-AI Summary
Alcon celebrates surpassing one million implants of AcrySof IQ Vivity and Clareon Vivity extended depth of focus intraocular lenses globally. Vivity, with its patented wavefront-shaping technology, offers excellent outcomes for cataract patients, addressing presbyopia and expanding patient candidacy pool.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
none
-
News

Alcon's Broad Portfolio Delivers Robust Sales and Earnings Growth in FY 2023

Rhea-AI Summary
Alcon (ALC) reported strong financial results for Q4 2023, with sales of $2.3 billion, up 8% or 10% constant currency, and diluted EPS of $0.86. FY 2023 sales were $9.4 billion, up 8%, and diluted EPS was $1.96. The company projects 6-8% sales growth and 13-16% core diluted EPS growth for FY 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
earnings
News

Alcon Canada Launches TOTAL30 Multifocal Contact Lenses for Reusable Lens Patients with Presbyopia

Rhea-AI Summary
Alcon has launched TOTAL30 Multifocal, the first monthly Water Gradient multifocal contact lens that provides excellent visual acuity at all distances, addressing the needs of the growing global multifocal market. The lens helps outsmart digital device dryness and presbyopia, which affects nearly 80% of people aged 45-55. The company aims to offer premium Water Gradient innovation at an accessible price point, with a proven fit success rate of 96%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
none
-
News

Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512, a Novel Topical Drug Candidate for Dry Eye

Rhea-AI Summary
Alcon (ALC) announced positive topline results from the two pivotal Phase 3 clinical trials (COMET-2 and COMET-3) evaluating the efficacy and safety of AR-15512, a candidate treatment for the signs and symptoms of dry eye disease (DED). In both trials, the primary endpoint of the proportion of subjects with at least a 10-mm increase in unanesthetized Schirmer’s score achieved statistical significance at Day 14 [p<0.0001]. Dry eye affects an estimated 38 million people in the U.S. and less than 10% of diagnosed patients are treated with a prescription product. AR-15512 has the potential to address the limitations of current dry eye prescription options and provide Eye Care Professionals (ECPs) and dry eye sufferers with a new and effective approach to the management of dry eye, a chronic and undertreated disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.54%
Tags
clinical trial
-
News

Alcon to Present at 2024 Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Alcon (ALC) CEO David Endicott to Present at 2024 J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
conferences
News

Alcon Reports Third Quarter 2023 Results

Rhea-AI Summary
Alcon (SIX/NYSE:ALC) reports strong Q3 2023 financial results with $2.3 billion in sales, up 8%, or 9% constant currency. Diluted EPS increased by 78%, or up 97% cc, and core diluted EPS up by 32%, or 41% cc. Operating margin improved by 3.0 percentage points, and the company generated $937 million of cash from operating activities and $592 million of free cash flow in the first nine months of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.91%
Tags
earnings
-
News

Alcon Canada Launches Clareon Vivity, its Latest Advancement in Presbyopia Correcting IOLs

Rhea-AI Summary
Alcon: Clareon Vivity, the first non-diffractive EDOF IOL with X-WAVE Technology, is now available in Canada, offering high-quality vision and spectacle independence for cataract patients. Surgeons can now provide patients with a lens designed to deliver optimal outcomes, comparable to a monofocal IOL, while minimizing visual disturbances. The lens features X-WAVE technology and glistening-free material, offering excellent distance, intermediate, and functional near vision.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
none
-
News

Alcon Showcases Cloud-based Planning and World-class Digital Technologies During AAO 2023

Rhea-AI Summary
Alcon announces full U.S. commercial availability of cloud-based cataract planner, SMARTCataract, which offers seamless connectivity for surgical ophthalmic practices. The platform has demonstrated significant time savings during the cataract evaluation, planning process, operating room, and postoperative workflow. Alcon will showcase its digital offerings at the upcoming American Academy of Ophthalmology (AAO) 2023 annual meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
none
News

Alcon Launches TOTAL30 Multifocal Contact Lenses for Patients with Presbyopia

Rhea-AI Summary
Alcon (SIX/NYSE: ALC) announced the global launch of TOTAL30® Multifocal, the first and only monthly Water Gradient multifocal contact lens. The lenses provide excellent visual acuity at all distances, addressing the vision and comfort needs of the global multifocal market, a rapidly growing market valued over $1 billion globally and growing double digit annually. The lenses have begun to roll out in the United States and select international markets, offering Alcon's premium Water Gradient innovation at a more accessible price point of monthly lenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
none

FAQ

What is the current stock price of Alcon Ordinary Shares (ALC)?

The current stock price of Alcon Ordinary Shares (ALC) is $84.76 as of December 20, 2024.

What is the market cap of Alcon Ordinary Shares (ALC)?

The market cap of Alcon Ordinary Shares (ALC) is approximately 41.6B.

What does Alcon Inc. specialize in?

Alcon Inc. specializes in eye care products, including contact lenses, lens care solutions, ocular health products, intraocular lenses (IOLs), and ophthalmic surgical equipment.

When did Alcon become an independent company?

Alcon became an independent public company in April 2019, following its spin-off from Novartis.

What are Alcon’s major product brands in the vision care segment?

Major product brands in Alcon’s vision care segment include Dailies, Total1, and Air Optix.

What significant recent product has Alcon launched?

Alcon recently launched the Clareon Vivity, the first non-diffractive extended depth of focus (EDOF) intraocular lens, incorporating wavefront-shaping technology.

How did Alcon perform financially in Q4 2023?

In Q4 2023, Alcon reported sales of $2.3 billion, an 8% increase from the previous year, with a diluted EPS of $0.86 and a core diluted EPS of $0.70.

What educational resources does Alcon offer?

Alcon offers educational resources through the Alcon Experience Academy, providing training and education for eye care professionals and supporting staff.

Where is Alcon Inc. headquartered?

Alcon Inc. is headquartered in Geneva, Switzerland and incorporated in Fribourg, Switzerland.

What segments does Alcon operate in?

Alcon operates in two main segments: vision care and surgical.

How has Alcon shown its commitment to innovation?

Alcon shows its commitment to innovation through continuous research and development, launching cutting-edge products like Clareon Vivity IOL, and partnerships with eye care professionals.

Who are the primary beneficiaries of Alcon's products?

The primary beneficiaries of Alcon's products are individuals with eye conditions such as cataracts, glaucoma, retinal diseases, and refractive errors, along with eye care professionals.

Stock ALC logo
Alcon Inc. Ordinary Shares

NYSE:ALC

ALC Rankings

#310 Ranked by Market Cap
#2084 Ranked by Dividends

ALC Stock Data

41.62B
493.82M
0.14%
66.79%
0.63%
Medical Instruments & Supplies
Healthcare
Link
United States of America
Geneva